William Blair Has Positive Outlook of NKTR FY2025 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Stock analysts at William Blair increased their FY2025 earnings per share estimates for Nektar Therapeutics in a research note issued to investors on Monday, July 14th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will post earnings per share of ($8.32) for the year, up from their previous forecast of ($11.69). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. William Blair also issued estimates for Nektar Therapeutics’ FY2026 earnings at ($11.25) EPS and FY2027 earnings at ($12.17) EPS.

Other research analysts have also recently issued research reports about the company. BTIG Research lifted their target price on Nektar Therapeutics from $60.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, June 24th. Wall Street Zen cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 14th. B. Riley lifted their target price on Nektar Therapeutics from $60.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. Jefferies Financial Group upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the company from $15.00 to $30.00 in a report on Friday, April 11th. Finally, HC Wainwright lifted their target price on Nektar Therapeutics to $120.00 and gave the company a “buy” rating in a report on Tuesday, June 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.33.

Nektar Therapeutics Trading Up 1.4%

Shares of Nektar Therapeutics stock opened at $24.14 on Wednesday. Nektar Therapeutics has a twelve month low of $6.48 and a twelve month high of $37.38. The stock has a market capitalization of $299.58 million, a P/E ratio of -2.52 and a beta of 0.94. The business’s fifty day moving average price is $15.08 and its 200 day moving average price is $13.12.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.70) by ($0.60). Nektar Therapeutics had a negative return on equity of 329.54% and a negative net margin of 152.49%. The business had revenue of $10.46 million for the quarter, compared to analyst estimates of $15.61 million. During the same quarter last year, the business earned ($2.70) EPS.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Palumbo Wealth Management LLC purchased a new position in Nektar Therapeutics in the second quarter valued at about $614,000. Voya Investment Management LLC raised its position in Nektar Therapeutics by 46.8% in the first quarter. Voya Investment Management LLC now owns 266,773 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 85,094 shares during the period. Rhumbline Advisers increased its position in shares of Nektar Therapeutics by 23.3% during the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 41,948 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Nektar Therapeutics by 1.4% during the first quarter. Acadian Asset Management LLC now owns 7,301,734 shares of the biopharmaceutical company’s stock worth $4,961,000 after acquiring an additional 100,645 shares during the last quarter. Finally, Fred Alger Management LLC purchased a new stake in shares of Nektar Therapeutics during the first quarter worth about $344,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.